Study of Lung and Gut Effects in Children with Cystic Fibrosis Using ElexacaftorTezacaftorIvacaftor Treatment

What this Trial Is About

Researchers are investigating the effects of the new combination treatment elexacaftortezacaftorivacaftor in children with cystic fibrosis, a disease that primarily affects the lungs and digestive system through chronic inflammation. This trial aims to understand how this treatment influences the lung and gut microbiota and inflammation. The study builds on previous research with a different treatment combination and uses an existing cohort and sample collection system to gather biological data over one year. Participants will receive elexacaftortezacaftorivacaftor as part of their routine care. Samples of sputum, stool, and blood will be collected at treatment start, six months, and one year later to analyze changes in lung and digestive bacterial and fungal communities. This approach allows researchers to study the interplay between the lung and gut microbiota during treatment. During the study, participants will provide biological samples at three time points for detailed microbiota and inflammation analysis. Researchers will measure the composition of digestive and pulmonary bacterial and fungal microbiota at baseline and after one year of treatment. The study lasts one year from treatment initiation, with ongoing monitoring to assess the treatments impact on these important health markers.

Intestine-lung Axis of Cystic Fibrosis Patients Treated With the Combination Elexacaftor/Tezacaftor/Ivacaftor